AJMC

State-Level Projections of Cancer-Related Medical Care Costs: 2010 to 2020

Published Online: September 20, 2012
Justin G. Trogdon, PhD; Florence K. L. Tangka, PhD; Donatus U. Ekwueme, PhD; Gery P. Guy Jr, PhD; Isaac Nwaise, PhD; and Diane Orenstein, PhD
Background: As the population ages, the financial amount spent on cancer care is expected to increase substantially. In this study, we projected cancer-related medical costs by state from 2010 through 2020.


Methods: We used pooled Medical Expenditure Panel Survey data for 2004 to 2008 and US Census Bureau population projections to produce state-level estimates of the number of people treated for cancer and the average cost of their treatment, from a health system perspective, by age group (18-44, 45-64, >65 years) and sex. In the base model, we assumed that the percentage of people in each of the 6 age-by-sex categories who had been treated for cancer would remain constant and that the inflation-adjusted average cancer treatment cost per person would increase at the same rate as Congressional Budget Office projections of overall medical spending.


Results: We projected that state-level cancer-related medical costs would increase by 34% to 115% (median = 72%) and that state-level costs in 2020 would range from $347 million to $28.3 billion in 2010 dollars (median = $3.7 billion).


Conclusions: The number of people treated for cancer and the costs of their cancer-related medical care are projected to increase substantially for each state. Effective prevention and early detection strategies are needed to limit the growing burden of cancer.


(Am J Manag Care. 2012;18(9):525-532)
Healthcare costs continue to rise nationally and impose greater burdens on state budgets.1 Since cancer-related medical care costs constitute a substantial portion of overall US medical care costs,2-4 accurate projections of future cancer-related care costs are critical. Over the past 20 years, the cost of treating cancer has nearly doubled nationally.2,5 As a result of an aging population and more expensive cancer treatments, the national costs of cancer care are expected to increase significantly in the near future.6 Although previous increases in spending on cancer have occurred despite the decreases in cancer incidence rates and increases in average survival times for patients with many types of cancers,7 researchers have noted many opportunities to further improve cancer detection and treatment while controlling costs.8-10

To take advantage of these opportunities, state-administered insurance providers such as Medicaid and public healthcare providers such as the National Breast and Cervical Cancer Early Detection Program11 need state-level projections of future cancer care costs. Previous projections of cancer prevalence and cancer care costs have focused only on the national level.6 This study produces state-level projections of cancer care costs through 2020. While our goal is not to explain differences across states, our projections do reflect projected changes in the distribution of state residents by age and sex during this period. They provide a useful baseline against which to gauge the impact of current and future cancer policies and could be useful for budget allocations for investments in cancer prevention and early detection.

DATA AND METHODS

Overview


First, we generated estimates of the number of adults who had been treated for cancer and the average cost of their treatment by age group (18-44, 45-64, >65 years) and sex (male, female). The small number of children with cancer in our data prevented reliable estimates for children. Second, in our base projections, we assumed that the treatment rate for cancer in each of the 6 age-by-sex groups would remain constant and that the inflationadjusted initial average cancer treatment cost per person would increase at the same rate as Congressional Budget Office (CBO) projections of overall medical spending.12,13 Third, we generated state-level projections of the total number of adults who will be treated for cancer and the costs of their treatment by multiplying treated cancer prevalence and average costs by the Census-projected population of each demographic cell. Therefore, the projections reflect expected changes in the distribution of state residents by sex and age group but assume that there will be no policy changes that could affect cancer treatment costs. For example, the projections do not account for possible changes in national healthcare policies mandated by the Affordable Care Act.

Projections of the Annual Number of US Adults Treated for Cancer

To estimate the number of adults in each state who will be treated for cancer, we used cancer prevalence data from the 2004 to 2008 Medical Expenditure Panel Survey (MEPS)14 and the US Census Bureau’s projections of state population counts for 2010 through 2020. The MEPS, a nationally representative survey of the civilian noninstitutionalized population administered by the Agency for Healthcare Research and Quality, provides data on participants’ use of medical services and on the costs of those services. MEPS provides a single, consistent data source to link disease prevalence and expenditures. Medical conditions are identified in the MEPS medical condition files; we restricted our condition indicators to those for which respondents received care within the interview year. Medical conditions were classified using the

International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes based on self-reported conditions that were transcribed by professional coders. Cancer was defined using clinical classification codes 11 through 43 and 45, which group ICD-9-CM codes into related groups.15 We combined cancers of any site.

We estimated logit models for the probability of cancer treatment that controlled for survey year and survey participants’ age, sex, and region of residence (northeast, south, midwest, and west). We used stepwise regressions to identify significant interactions among these variables to be included in the models. The significant interactions in the stepwise regressions represent age-by-sex-by-region categories with enough sample and power to detect differences in cancer treatment rates. We estimated cancer treatment rates (ie, the proportion of the population treated for cancer) for US adults in each age/sex/region group using coefficients from the logit regressions and adjusted these estimates to account for the nursing home care population using data from the 2004 National Nursing Home Survey.

We used the projected state population counts for 2010 through 2020 generated in 2008 by the US Census Bureau on the basis of data from the 2000 Census.16 For each state, we multiplied the predicted percentage of people treated for cancer in each of the 6 age-by-sex categories by the projected number of state residents in the corresponding category for each year from 2010 through 2020. We then aggregated these projections to project the total number of people who will be treated for cancer in each state in each year.

Projections of Direct Medical Care Costs of Cancer

MEPS measures total annual medical spending, including payments by insurers and out-of-pocket spending by patients (copayments, deductibles, and payments for noncovered services). The costs captured by MEPS represent payments (not charges) from the payer to the provider. MEPS spending data are obtained through a combination of self-reports by the respondents and validation of the self-reports from payers.17

PDF is available on the last page.

Issue: September 2012
More on AJMC.COM